195 related articles for article (PubMed ID: 31053766)
1. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Ryan CJ; Dutta S; Kelly WK; Russell C; Small EJ; Morris MJ; Taplin ME; Halabi S;
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):66-73. PubMed ID: 31053766
[TBL] [Abstract][Full Text] [Related]
2. Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
[TBL] [Abstract][Full Text] [Related]
3. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
Kim W; Zhang L; Wilton JH; Fetterly G; Mohler JL; Weinberg V; Morse A; Szmulewitz RZ; Friedlander TW; Fong L; Lin AM; Harzstark AL; Molina A; Small EJ; Ryan CJ
Clin Cancer Res; 2014 Dec; 20(24):6269-76. PubMed ID: 25336698
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
[TBL] [Abstract][Full Text] [Related]
5. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
8. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
9. Androgen dynamics and serum PSA in patients treated with abiraterone acetate.
Ryan CJ; Peng W; Kheoh T; Welkowsky E; Haqq CM; Chandler DW; Scher HI; Molina A
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):192-8. PubMed ID: 24637537
[TBL] [Abstract][Full Text] [Related]
10. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
12. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
[TBL] [Abstract][Full Text] [Related]
13. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
14. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract][Full Text] [Related]
15. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
16. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
[TBL] [Abstract][Full Text] [Related]
18. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
19. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
20. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]